Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...

Over a decade into selling Korlym to treat endogenous hypercortisolism, also known as Cushing syndrome, Corcept Therapeutics ...

Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Argenx Se, and Wave Life Sciences. Currently, the analyst consensus on Corcept Therapeutics is a Strong Buy with an ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a ...

Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6.Pick the best ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast Truist Securities raises the price target for Corcept Therapeutics to $76 ...

Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...